Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

l session, results of an ongoing trial of ISIS 301012 added to maximal lipid lowering therapies in homozygous familial hypercholesterolemia (FH) patients were reported. Results of polygenic hypercholesterolemic patients treated with up to 400 mg/week of ISIS 301012 for up to three months as a single agent are the subject of a v-cast poster presentation. Results for the extended three-month treatment cohorts at 200 and 300 mg/week doses in the statin coadministration study are expected later in the year. Also later in the year, results from an ongoing double-blind, placebo-controlled, dose-escalation study in patients with heterozygous FH will be reported.

ISIS 301012 has been granted orphan drug status for the treatment of homozygous FH and Isis plans to begin registration-directed studies for FH in 2007.

About ISIS 301012 and Cholesterol

ISIS 301012 is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol and a target that has proved to be undruggable using traditional, small-molecule approaches. Cholesterol can be carried in the bloodstream in a variety of forms, with high-density lipoprotein, or HDL-C, being the good form, and low-density lipoproteins, or LDL-C, and very low-density lipoproteins, or VLDL-C, being bad forms directly involved in heart disease. Collectively, LDL-C, VLDL-C, and other bad forms of cholesterol are referred to as "non-HDL-C." The lowering of non-HDL-C is a key component in the prevention and management of cardiovascular disease. Isis plans to develop ISIS 301012 as the drug of choice for patients who are unable to achieve target cholesterol levels with statins alone or who are intolerant of statins.

Adult Treatment Panel III Recommendations

The National Cholesterol Education Program's Adult Treatment Panel III guidelines for target LDL-C levels High-Risk patients is less than 100 mg/dL, with an optional target
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:4/17/2015)... 2015 Sigma-Aldrich Corporation (NASDAQ: ... High Technology company, today announced the opening of ... and state-of-the-art Cell Culture Technical Center in Singapore.  ... provide customized support to meet customer needs, leveraging ... "Our new Technical Center will significantly enhance our ...
(Date:4/17/2015)... , April 17, 2015 TWi Pharmaceuticals, Inc. ... TWi Pharmaceuticals USA , has obtained ... United States.  It has been in close contact with ... expects to have its own label specialty generic products ... the U.S. pharma market. According to IMS ...
(Date:4/16/2015)... SHENZHEN, China , April 16, 2015 /PRNewswire/ ... a leading developer, manufacturer, and marketer of medical ... with the Securities and Exchange Commission an Annual Report ... for the year ended December 31, 2014. An electronic ... is available on Mindray,s investor relations website at  ...
Breaking Medicine Technology:Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 3Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 4Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 5Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2
... Verenium Corporation (Nasdaq: VRNM ), a ... solutions, today announced a series of changes within its senior ... Carlos Riva, currently Director, President and Chief Executive Officer, will ... continue to be available to the Company as a consultant ...
... MOUNTAIN VIEW, Calif., Feb. 25, 2011 VIVUS, Inc. ... Morris, chief financial officer, will present an overview of ... of March.  The conference presentation schedule is as follows:Citi,s ... p.m. ETHilton New York Hotel, New York, NYCowen and ...
Cached Medicine Technology:Verenium Announces Changes in Senior Management 2Verenium Announces Changes in Senior Management 3
(Date:4/17/2015)... As a board-certified orthopedic surgeon, Dr. Steven ... platelet-rich plasma (PRP) and stem cell therapy. ... for its world-class care of injury-caused and chronic joint ... in many other physicians offering regenerative medicines. , ... pain management and rehabilitation. Dr. Meier and MOSM can ...
(Date:4/17/2015)... Baptist Health and The University of Texas ... designed to transform oncology care in northeast Florida and ... create a joint cancer program to enhance patient access ... MD Anderson Cancer Center is anticipated to open in ... highly coordinated, multidisciplinary cancer care for adults in the ...
(Date:4/17/2015)... Connie Casad, M.D., a well-known and respected ... 30 years of practice experience in Dallas, Texas, has ... service for her patients with the availability of a ... books with a brief synopsis on each for her ... in providing this service, Dr. Casad said, “Furnishing a ...
(Date:4/17/2015)... NJ (PRWEB) April 17, 2015 ... in the posterior pituitary and thought to help mothers ... between couples. To further substantiate this, new studies performed, ... the journal, Nature, and reported by Medical News Today ... a powerful influence over maternal social behavior. The study ...
(Date:4/17/2015)... 2015 Ticket Down is a reputable source of ... Tour. , The life of last-minute show announcements is where fans ... perform during the early part of 2015, but beginning in June, ... Lion Man,” “The Cave,” and “Believe,” will perform a full-fledged tour ... at MCU Park at Coney Island in Brooklyn, NY and ends ...
Breaking Medicine News(10 mins):Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Connie Casad, M.D. Provides Patients Recommended List of Wellness Books on Website 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 3Health News:Mumford and Sons Tickets in Clarkston/Detroit, Raleigh, Columbia/Baltimore, Chicago, Mansfield/Boston, Brooklyn, Calgary and Edmonton Now On Sale 2
... N.J. and MONTVALE, N.J., Nov. 25 Roche and ... that the two companies have signed a definitive merger ... of Memory Pharmaceuticals in an all-cash transaction for an ... , Memory Pharmaceuticals develops ...
... Vitech Systems Group, Inc. (Vitech) has completed phase ... the Iowa Public Employees, Retirement System (IPERS). IPERS, one ... contracted with Vitech in 2006 to implement and maintain ... capabilities and increases efficiency, transforming IPERS, business. , ...
... PhD student, Dr Sue Lynn Lau, had won the Graduate ... PhD" contest. See her winning entry on YouTube. , On ... world to interpret their PhD research in dance form, film ... by mid-November. A total of 36 dances - including ...
... 2008 Forest Laboratories, Inc. (NYSE: FRX ) ... has closed prosecution on the merits of the reexamination proceedings ... all of the previously granted claims. As a result, the ... Parte Reexamination Certificate for U.S. Patent No. 6,545,040 (the ,040 ...
... receptor cuts the urge for nicotine, rat study suggests , , ... in the brain may be one way to quickly lessen ... Hypocretin-1, or Orexin A, a short chain of amino acids ... closely linked biochemical reactions that makes lab rats crave nicotine, ...
... with an impermeable sleeve led to both weight loss ... model of obesity-induced diabetes. Investigators from the Massachusetts ... in the journal Obesity that the procedure ... a significant reduction in the animals, food intake and ...
Cached Medicine News:Health News:Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals 2Health News:Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals 3Health News:Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals 4Health News:Vitech's V3 Pension Administration Software Improves IPERS' Business 2Health News:Ph.D. student Sue Lynn Lau dances her way to Chicago 2Health News:USPTO Confirms Validity of Bystolic(R) Patent 2Health News:Molecular Switch in Brain May End Smokers' Cravings 2Health News:Sealing off portion of intestinal lining treats obesity, resolves diabetes in animal model 2Health News:Sealing off portion of intestinal lining treats obesity, resolves diabetes in animal model 3
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
... The Vibratome Roto-Shake Genie is an ... It performs five different mixing ... and rotating/rolling, as well as a ... The precision-engineered moving portion of the ...
... The Vibratome Roto-Shake Genie is ... platform. It performs five different ... rolling/rocking and rotating/rolling, as well as ... The precision-engineered moving portion of ...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Medicine Products: